Abbott Laboratories is digesting some
painful news about its blockbuster heartburn
medication.
A high-profile whistleblower has sued TAP
Pharmaceuticals, a joint venture half-owned by Abbott,
for allegedly overbilling Medicaid for Prevacid -- a
drug that, last quarter, generated nearly three times
more revenue than Abbott's second-best-selling drug.
New Orleans physician John LaCorte, who has
already won other whistleblower lawsuits, claims that
TAP violated its agreement to offer Medicaid its "best
price" for Prevacid by charging the agency up to 20
times more for the drug than it charged some of its
other customers. LaCorte sued TAP on behalf of the
federal government and is seeking triple damages, plus
a $10,000 fine for each violation. He alleges
fraudulent behavior that, he says, dates back more
than a decade.
The government itself has so far declined to
pursue the lawsuit, and TAP denies any wrongdoing. The
company says it "prices its products in full
compliance with federal and state laws and
regulations" and that it will "vigorously" defend
itself against the allegations.
Marc Vezina, the New Orleans attorney representing
LaCorte, says that LaCorte will "absolutely" move
forward with the case even without government help.
"My client feels very strongly about this," he
says. The company must formally respond to the lawsuit
in court by Oct. 1, Vezina says.
Some industry watchers believe total penalties in
the case could exceed the big fine TAP has already
paid for overbilling the government for its
other major drug. Three years ago, TAP paid $875
million to settle allegations that it had
overcharged the government for Lupron. That drug, used
to treat advanced prostate cancer, last quarter
generated only 25% as much revenue as Prevacid did.
Although TAP agreed to pay the fine, the company
maintained its innocence on many of the charges
against it.
Some now view the current case as more damaging.
"I think it's safe to say this case is huge --
hundreds and hundreds of millions of dollars, without
a doubt," says Patrick Burns, director of
communications for Taxpayers Against Fraud. "In fact
... TAP's liability could easily be well over $1
billion."